

Supplementary material

A retrospective, longitudinal, registry study on the long-term durability of ivacaftor treatment in people with cystic fibrosis

Christian Merlo¹; Teja Thorat²; Lisa J. McGarry²; Christina V. Scirica²; Maral DerSarkissian³; Catherine Nguyen³; Yuqian M. Gu³; Aruna Muthukumar³; Joe Healy²; Jaime L. Rubin²; M. Alan Brookhart⁴

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Vertex Pharmaceuticals Incorporated, Boston, MA, USA; ³Analysis Group, Inc., Los Angeles, CA, USA; ⁴Duke University, Durham, NC, USA

Corresponding author:

Christian Merlo, MD, MPH

Email: cmerlo@jhmi.edu

Table S1. CFTR gating mutations (legacy name)

G551D
G178R
S1255P
S549N
S549R
G551S
G1244E
S1251N
G1349D

CFTR: cystic fibrosis transmembrane conductance regulator.

Table S2. Minimal function CFTR mutations (legacy name)

1078delT	3120+1G->A	A559T	Q552X
1154insTC	3120G->A	A561E	Q890X
1161delC	3121-1G->A	C276X	Q98X
1213delT	3600+2insT	CFTRdele19	R1066C
1248+1G->A	3659delC	CFTRdele2	R1158X
1259insA	3667ins4	CFTRdele2,3	R1162X
1288insTA	3737delA	CFTRdele22-24	R347P
1341+1G->A	3791delC	CFTRdele22,23	R553X
1461ins4	3821delT	E1104X	R560S
1525-1G->A	3850-1G->A	E585X	R560T
1548delG	3876delA	E60X	R709X
1677delTA	3905insT	E822X	R75X
1717-1G->A	394delTT	E92X	R764X
1717-8G->A	4005+1G->A	G330X	R785X
1811+1.6kbA->G	4016insT	G542X	R792X
1811+1G->C	4040delA	G673X	R851X
1812-1G->A	405+1G->A	G85E	S1196X
1898+1G->A	405+3A->C	I507del	S1255X
2043delG	406-1G->A	K710X	S434X
2055del9->A	4209TGTT->AA	L1065P	S466X
2105-	4326delITC	L1077P	S489X
2117del13insAGAAA	4374+1G->T	L218X	S912X
2143delT	444delA	L467P	V520F
2183AA->G	457TAT->G	L732X	W1089X
2184delA	541delC	M1101K	W1204X
2184insA	574delA	N1303K	W1282X
2307insA	621+1G->T	Q1313X	W401X
2347delG	663delT	Q220X	W496X
2585delT	711+1G->T	Q290X	W57X
2622+1G->A	711+5G->A	Q39X	W846X
2711delT	712-1G->T	Q414X	Y1092X
2869insG	852del22	Q493X	Y122X
2896insAG	935delA	Q525X	Y569D
3007delG	A46D		
306insA			

CFTR: cystic fibrosis transmembrane conductance regulator.